Author:
Rothstein David M,Suchland Robert J,Xia Minsheng,Murphy Christopher K,Stamm Walter E
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology
Reference29 articles.
1. Fujii K, Saito H, Tomioka H, Mae T, Hosoe K . Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob Agents Chemother 39: 1489–1492 ( 1995)
2. Dietze R . Teixeira L, Rocha LM, Palaci M, Johnson JL, Wells C, Rose L, Eisenach K, Ellner JJ . Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 45: 1972–1976 ( 2001)
3. Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI . Development potential of rifalazil. Expert Opin Investig Drugs 12: 255–271 ( 2003).
4. Roblin PM, Reznik T, Kutlin A, Hammerschlag MR . In vitro activities of rifamycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 47: 1135–1136 ( 2003)
5. Stamm WE, Geisler WM, Suchland RJ . Assessment of antimicrobial resistance in Chlamydia trachomatis strains associated with treatment failure or same strain recurrence, pp. 353–360. In Chlamydial infections: Proceedings of the 10th International Symposium on Human Chlamydial Infections. Basim Yeri: GRAFMAT Basim ve Reklam Sanayi Tic. Ltd. Sti., Antalya, Turkey ( 2002)
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献